Evicenter
Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Questions
28
Last updated

All questions

Clinical trials: Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

13 questions · 5 sources

Clinical trials

Who was studied in the Ibrance PALOMA-2 trial?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

“PALOMA-2 was an international, randomized, double-blind, parallel-group, multicenter study of IBRANCE plus letrozole versus placebo plus letrozole conducted in postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous systemic treatment for their advanced disease. A total of 666 patients were randomized 2:1 to IBRANCE plus letrozole or placebo plus letrozole. Randomization was stratified by disease site (visceral versus non-visceral), disease-free interval (de novo metastatic versus ≤12 months from the end of adjuvant treatment to disease recurrence versus >12 months from the end of adjuvant treatment to disease recurrence), and nature of prior (neo)adjuvant anticancer therapies (prior hormonal therapies versus no prior hormonal therapy). IBRANCE was given orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days off treatment. Patients received study treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. The major efficacy outcome of the study was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST). Additional efficacy outcome measures were confirmed overall response rate (ORR) as assessed by the investigator according to RECIST Version 1.1 and overall survival (OS).” (opens the source at this quote in a new tab)

Who was studied in the Ibrance PALOMA-3 trial?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

Study results

How long does Ibrance plus letrozole delay progression vs letrozole alone (PALOMA-2)?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

Note: Table 12 columns are IBRANCE plus letrozole and placebo plus letrozole, in that order.

Does Ibrance plus letrozole help patients live longer (PALOMA-2 overall survival)?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

What was the response rate with Ibrance plus letrozole (PALOMA-2)?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

How long does Ibrance plus fulvestrant delay progression vs fulvestrant alone (PALOMA-3)?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

Note: Table 13 columns are IBRANCE plus fulvestrant and placebo plus fulvestrant, in that order.

Does Ibrance plus fulvestrant help patients live longer (PALOMA-3 overall survival)?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

What was the response rate with Ibrance plus fulvestrant (PALOMA-3)?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

How long did patients take Ibrance in PALOMA-2 and PALOMA-3?

Subgroup results

Were Ibrance plus letrozole results consistent across subgroups (PALOMA-2)?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

Were Ibrance plus fulvestrant results consistent across subgroups (PALOMA-3)?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

Long-term data

What are the long-term side effects of Ibrance plus letrozole (PALOMA-2)?

Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

What are the long-term side effects of Ibrance plus fulvestrant (PALOMA-3)?

Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)